CBIO
Crescent Biopharma
CBIO
CBIO
78 hedge funds and large institutions have $535M invested in Crescent Biopharma in 2019 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 31 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
6% less capital invested
Capital invested by funds: $567M → $535M (-$31.2M)
23% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 31
95% less call options, than puts
Call options by funds: $74K | Put options by funds: $1.45M
Holders
78
Holding in Top 10
1
Calls
$74K
Puts
$1.45M
Top Buyers
| 1 | +$56.8M | |
| 2 | +$4.3M | |
| 3 | +$3.69M | |
| 4 |
Nuveen Asset Management
Chicago,
Illinois
|
+$1.69M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.43M |
Top Sellers
| 1 | -$4.53M | |
| 2 | -$4.3M | |
| 3 | -$3.88M | |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.41M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.15M |